Therefore, dual modality therapy consisting of anti-EGFR and radiotherapy was rationally designed utilizing Cetuximab, a chimeric IgG1 antibody, and this was the first combination of targeted therapy with EBRT to receive FDA-approval for the treatment of locally advanced HNSCC [18]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.